Enterprise Value
997.2M
Cash
71.32M
Avg Qtr Burn
-15.82M
Short % of Float
0.13%
Insider Ownership
0.00%
Institutional Own.
1.70%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease | BLA FDA meeting | |
REVASCOR® (Rexlemestrocel) Details Heart disease, Heart failure | Phase 3 Update | |
Rexlemestrocel Details Chronic lower back pain | Phase 3 Initiation | |
Remestemcel-L Details Inflammatory bowel disease, Bowel disorder, Crohns disease | Failed Discontinued | |
Failed Discontinued |